/CNSP

CNSP Stock - CNS Pharmaceuticals, Inc.

Q: What is the analyst price target for CNSP?

Analyst price target information is not currently available for CNSP.

Q: What is CNSP's market cap?

Market capitalization information is not currently available for CNSP.

Healthcare|Biotechnology|NASDAQ

$6.51-2.54%

$0.17 (-2.54%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

SELL

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-92.3%upside

Target: $0.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CNSP

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.45

52W High$114.00

52W Low$4.93

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-3,306	$-4,134	$-11,756	$-13,070	$-11,096
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-14,901,943	$-18,865,108	$-14,932,969	$-14,485,915	$-9,454,607
Net Income	$-14,857,801	$-18,851,226	$-15,274,134	$-14,495,200	$-9,457,871
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-38.87	$-60.00	$-134.64	$-6.36	$-6.84

Company Overview

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Visit Website

Earnings History & Surprises

CNSP

Beat Rate

53%

Last 17 quarters

Avg Surprise

-103675.9%

EPS vs Estimate

Beats / Misses

9/8

Last 12 quarters

Latest EPS

$-5.76

Q4 2025

EPS Surprise History

Q3 23

+63.1%

$-31212.48vs$-84600.00

Q4 23

+37.5%

$-32412.97vs$-51900.00

Q2 24

+50.0%

$-28511.40vs$-57000.00

Q2 24

No data

Q3 24

-12.5%

$-4033.61vs$-3585.43

Q4 24

-149960.0%

$-150.06vs$-0.10

Q3 25

+33.1%

$-6.42vs$-9.60

Q4 25

+13.1%

$-5.76vs$-6.63

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 13, 2026	—	—	—	—
Q4 2025	Nov 14, 2025	$-6.63	$-5.76	+13.1%	✓ BEAT
Q3 2025	Aug 14, 2025	$-9.60	$-6.42	+33.1%	✓ BEAT
Q4 2024	Nov 14, 2024	$-0.10	$-150.06	-149960.0%	✗ MISS
Q3 2024	Aug 14, 2024	$-3585.43	$-4033.61	-12.5%	✗ MISS
Q2 2024	May 15, 2024	—	$-12304.92	—	—
Q2 2024	Apr 1, 2024	$-57000.00	$-28511.40	+50.0%	✓ BEAT
Q4 2023	Nov 14, 2023	$-51900.00	$-32412.97	+37.5%	✓ BEAT
Q3 2023	Aug 14, 2023	$-84600.00	$-31212.48	+63.1%	✓ BEAT
Q2 2023	May 15, 2023	—	$-77731.09	—	—
Q1 2023	Mar 31, 2023	$-6000.00	$-2.23	+100.0%	✓ BEAT
Q4 2022	Nov 10, 2022	$-2.40	$-8104.05	-337568.8%	✗ MISS
Q3 2022	Aug 12, 2022	$-2.40	$-8104.05	-337568.8%	✗ MISS
Q2 2022	May 16, 2022	$-2.40	$-6303.15	-262531.3%	✗ MISS
Q1 2022	Mar 3, 2022	$-18909.45	$-9004.50	+52.4%	✓ BEAT
Q4 2021	Nov 12, 2021	$-18909.45	$-12606.30	+33.3%	✓ BEAT
Q3 2021	Aug 13, 2021	$-14407.20	$-13506.75	+6.3%	✓ BEAT
Q2 2021	May 14, 2021	$-3.60	$-13506.75	-375087.5%	✗ MISS
Q1 2021	Feb 12, 2021	$-8104.05	$-16208.10	-100.0%	✗ MISS
Q4 2020	Nov 12, 2020	$-3.60	$-10805.40	-300050.0%	✗ MISS

Frequently Asked Questions about CNSP

What is CNSP's current stock price?

CNS Pharmaceuticals, Inc. (CNSP) is currently trading at $6.51 per share. The stock has moved -2.54% today.

What is the analyst price target for CNSP?

The average analyst price target for CNSP is $0.50, based on 1 analyst.

What sector is CNS Pharmaceuticals, Inc. in?

CNS Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CNSP's market cap?

CNS Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does CNSP pay dividends?

No, CNS Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.